BR112022006458A2 - INOSITOL PHOSPHATE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION OR PREVENTION OF CARDIOVASCULAR CALCIFICATION - Google Patents
INOSITOL PHOSPHATE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION OR PREVENTION OF CARDIOVASCULAR CALCIFICATIONInfo
- Publication number
- BR112022006458A2 BR112022006458A2 BR112022006458A BR112022006458A BR112022006458A2 BR 112022006458 A2 BR112022006458 A2 BR 112022006458A2 BR 112022006458 A BR112022006458 A BR 112022006458A BR 112022006458 A BR112022006458 A BR 112022006458A BR 112022006458 A2 BR112022006458 A2 BR 112022006458A2
- Authority
- BR
- Brazil
- Prior art keywords
- calcification
- progression
- inhibition
- prevention
- treatment
- Prior art date
Links
- 230000002308 calcification Effects 0.000 title abstract 6
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 4
- 230000005764 inhibitory process Effects 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical class OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 title abstract 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 abstract 2
- 206010050559 Aortic valve calcification Diseases 0.000 abstract 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229960000367 inositol Drugs 0.000 abstract 1
- -1 inositol phosphates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSTOS DE INOSITOL FOSFATO PARA USO NO TRATAMENTO, INIBIÇÃO DA PROGRESSÃO OU PREVENÇÃO DA CALCIFICAÇÃO CARDIOVASCULAR. A presente invenção se refere a compostos, composições farmacêuticas, preparações combinadas, e regimes de dosagem para o tratamento, inibição da progressão, e prevenção da calcificação cardiovascular, e em particular, calcificação coronária, calcificação da artéria aorta, e calcificação da válvula aórtica compreendendo inositol fosfatos. Em um aspecto particular a divulgação fornece um regime de dosagem para o tratamento, inibição da progressão ou prevenção da calcificação cardiovascular compreendendo a administração de cerca de 200 mg a cerca de 700 mg de mio-inositol hexafosfato por administração.INOSITOL PHOSPHATE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, OR PREVENTION OF CARDIOVASCULAR CALCIFICATION. The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for the treatment, inhibition of progression, and prevention of cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression or preventing cardiovascular calcification comprising administering from about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382990.0A EP3818983A1 (en) | 2019-11-11 | 2019-11-11 | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
| EP2021094331 | 2021-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022006458A2 true BR112022006458A2 (en) | 2022-06-28 |
Family
ID=83356164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022006458A BR112022006458A2 (en) | 2019-11-11 | 2020-11-10 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION OR PREVENTION OF CARDIOVASCULAR CALCIFICATION |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR112022006458A2 (en) |
-
2020
- 2020-11-10 BR BR112022006458A patent/BR112022006458A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zekri et al. | The anti-tumour effects of zoledronic acid | |
| MX2022004971A (en) | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification. | |
| Chen et al. | Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models | |
| Moeenfard et al. | Anti‐angiogenic properties of Cafestol and Kahweol palmitate diterpene esters | |
| Belli et al. | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer | |
| Chen et al. | Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species | |
| EA033448B1 (en) | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | |
| Karim et al. | Chemotherapy for small cell lung cancer: a comprehensive review. | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| Culver et al. | Ipilimumab: a novel treatment for metastatic melanoma | |
| BR112022015151A2 (en) | METHOD FOR REDUCING OR PREVENTING PROGRESSION OF A TUMOR OR TREATING CANCER, AND, COMPOSITION | |
| BR112022008000A2 (en) | PYRAZOLE-HETEROARYL DERIVATIVE, PREPARATION METHOD FOR IT AND MEDICAL USE THEREOF | |
| Ouyang et al. | Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway | |
| BR112021025477A2 (en) | Parenteral lysophosphatidylcholine formulations like lpc-dha, lpc-epa and their uses in therapy | |
| BR112019003533A2 (en) | combination therapy with glutaminase inhibitors | |
| TN2022000113A1 (en) | Dosing regimen for anti-dll3 agents | |
| Caffo | Radiosensitization with chemotherapeutic agents | |
| JOP20200014A1 (en) | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| AR110800A1 (en) | METHODS TO INCREASE 2'-DEOXYURIDINE (dUrd) IN BLOOD PLASMA AND THE INHIBITION OF THYMIDYLATE SYNTHASE | |
| Koto et al. | Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents | |
| BR112022006458A2 (en) | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION OR PREVENTION OF CARDIOVASCULAR CALCIFICATION | |
| Eum et al. | Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials | |
| Rogovskii | Polyphenols as the potential disease-modifying therapy in cancer | |
| Guel-Klein et al. | Is PIPAC a treatment option in Upper and lower gastrointestinal cancer with peritoneal metastasis? | |
| MX2024005721A (en) | Inositol phosphates for the treatment of ectopic calcification. |